---
layout: post
title: FDA因血栓风险限制强生新冠疫苗的授权使用
date: 2022-05-06 07:33:03.000000000 +08:00
link: https://cn.wsj.com/amp/articles/fda%E5%9B%A0%E8%A1%80%E6%A0%93%E9%A3%8E%E9%99%A9%E9%99%90%E5%88%B6%E5%BC%BA%E7%94%9F%E6%96%B0%E5%86%A0%E7%96%AB%E8%8B%97%E7%9A%84%E6%8E%88%E6%9D%83%E4%BD%BF%E7%94%A8-11651792808
categories: wsj
---

<main id="main" role="main">
<div>


</div>
<div itemprop="articleLead" data-sbId="CN-BIZ-20220506070830">
    <div>
      <div class="media-object scope-
          header
">
          <figure>
      <div>
        <img
          srcset="https://images.wsj.net/im-521832?width=540&amp;size=1.5005861664712778 540w, https://images.wsj.net/im-521832?width=620&amp;size=1.5005861664712778 620w, https://images.wsj.net/im-521832?width=639&amp;size=1.5005861664712778 639w, https://images.wsj.net/im-521832?width=860&amp;size=1.5005861664712778 860w, https://images.wsj.net/im-521832?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=1.5 1290w, https://images.wsj.net/im-521832?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=2 1720w, https://images.wsj.net/im-521832?width=860&amp;size=1.5005861664712778&amp;pixel_ratio=3 2580w"
          src="https://images.wsj.net/im-521832?width=860&amp;height=573"
          layout="responsive"
          placeholder
          alt="">
        </img>
      </div>
      <figcaption>
        <p> 图片来源：Adele Morgan</p>
  </figcaption>
</figure>

      </div>
    </div>
</div>
<div data-sbId="CN-BIZ-20220506070830">

<div>

  <div>
      <p> </p>
              <p><span itemprop="name">
                <a href="https://www.wsj.com/news/author/liz-essley-whyte" itemprop="url" rel="author">Liz Essley Whyte</a>
              </span> / </p>
            <p><span itemprop="name">
                <a href="https://www.wsj.com/news/author/peter-loftus" itemprop="url" rel="author">Peter Loftus</a>
              </span></p>

  </div>
    <time>
      2022年5月6日07:20 CST 更新
    </time>
</div>

<div>
  <social-share type="system" width="72" height="24"
    data-param-url="https://cn.wsj.com/articles/fda因血栓风险限制强生新冠疫苗的授权使用-11651792808">
  </social-share>
</div>


<div subscriptions-section="content">
</div>
<div subscriptions-section="content-not-granted">
</div>



<section subscriptions-section="content">
      <p>美国食品药品管理局(Food and Drug Administration, 简称FDA)在评估了强生公司(Johnson &amp; Johnson, JNJ)新冠疫苗威胁生命的血栓风险后，限制了该疫苗的使用。</p>
      <p>FDA周四表示，在确认数百万接种强生疫苗的患者中，共有60例出现血栓性血小板减少综合征(TTS)，包括9例死亡后，该机构采取了这一举措。</p>
      <p>卫生当局曾希望这种疫苗对许多人来说是一个方便的选择，但由于出现了<a href="https://cn.wsj.com/articles/CN-BIZ-20210414071427" target="_blank" >罕见但危及生命的副作用</a>，这种疫苗已成为大多数人的第三选择。FDA的这一改变可能将大幅削减这种疫苗的使用。</p>
      <div> <p>由于存在风险，美国疾病控制与预防中心(The Centers for Disease Control and Prevention, 简称CDC)去年12月建议患者选择其他疫苗，而不是强生公司的疫苗。</p>
      </div>
</section>

</div>
      </main>
